U.S. pharma large copyright scrapped two experimental weight loss pills final yr—a once-day by day tablet, lotiglipron, resulting from elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, because of sturdy Unwanted side effects—but CEO Albert Bourla has reported